Education Blog for Healthcare Professionals

ACCP Guideline for DVT and PE Treatment: New Edition, 2016

| Comments Off on ACCP Guideline for DVT and PE Treatment: New Edition, 2016

The ACCP Chest Guidelines have been the main guide over the last more than 2 decades for evidence-based recommendations on best management of anticoagulants for various indications, including DVT and PE.  The 10th edition of the chapter on DVT and PE management was published in Jan 2016 [ref 1]. Unfortunately, the guideline is not available for non-subscribers. Read the rest of this entry »

Scuba Diving While on an Anticoagulant

| Comments Off on Scuba Diving While on an Anticoagulant

Stephan Moll, MD writes… Can patients on anticoagulants safely scuba dive?  In general: “Yes”.  Many people who take anticoagulants are able to safely dive.  However, there are a few things to consider: Read the rest of this entry »

MTHFR and Homocysteine: Information Handout for Patients

| Comments Off on MTHFR and Homocysteine: Information Handout for Patients

Stephan Moll, MD writes… A plain language summary for patients and interested public about homocysteine and the MTHFR mutations and their relevance in respect to thrombosis was  published today in the journal Circulation (link here).

Reference:  Moll S, Varga EA.  Homocysteine and MTHFR Mutations. Circulation. 2015;132:e6-e.

Thrombophilia – Information Handout for Patients

| Comments Off on Thrombophilia – Information Handout for Patients

Stephan Moll, MD writes… An information article on various aspects of thrombophilia, written for patients and family members, was published today – available here – as a Vascular Disease Patient Information Page in the journal Vascular Medicine.  It addresses (a) in which patient with venous thromboembolism to consider thrombophilia  testing, (b) what tests might be appropriate to do, (c) how the test results might influence length of anticoagulation therapy (d), what contraceptives are safe to use in women with a history of DVT or PE or thrombophilia, and (e)  in which family members to consider thrombophilia testing.  This article can be used as an education handout for patients in clinic or the hospital who have DVT, PE, venous thrombosis in unusual locations, or an established thrombophilia.

 

Disclosures:  None

Last updated: April 1st, 2015

ASH 2014 Highlights: Thrombosis and Anticoagulation

| Comments Off on ASH 2014 Highlights: Thrombosis and Anticoagulation

Stephan Moll, MD writes... The annual American Society of Hematology (ASH) meeting took place in Dec 2014 in San Francisco.  A summary of the clinically relevant thrombosis and anticoagulation presentation and abstracts is presented here (Top 10 ASH Highlights).

 

Disclosure: I have been a consultant to Portola, Daiichi, Janssen, and Boehringer-Ingelheim. 

Last updated: Jan 27th, 2015

Fourth NOAC FDA Approved for DVT, PE and Atrial Fibrillation: Savaysa (Edoxaban)

| Comments Off on Fourth NOAC FDA Approved for DVT, PE and Atrial Fibrillation: Savaysa (Edoxaban)

Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release  is here (link).  Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The detailed drug package insert with dosing information is here (link). Read the rest of this entry »

Two Things Physicians Should Avoid

| Comments Off on Two Things Physicians Should Avoid

Stephan Moll, MD writes (Dec 17, 2014)…  The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1]. Read the rest of this entry »

Fascinating New “Anticoagulant”: It Protects from VTE, but Does Not Increase Bleeding

| Comments Off on Fascinating New “Anticoagulant”: It Protects from VTE, but Does Not Increase Bleeding

Stephan Moll, MD writes (on Dec 8th, 2014)… A publication this week in the New England Journal of Medicine reports on an investigational drug that protects patients from VTE without increasing the risk of bleeding [reference below]. Too good to be true? Possibly, but may be not. Additional studies will have to tell. Read the rest of this entry »